Niosomal Hydrogel Loaded With Bromelain: A Promising Solution for Reducing Skin Collagen in Scleroderma Patients

Early human evidence such as case series or small samples is exploring possible benefits.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Skin fibrosis in scleroderma is a chronic and debilitating condition that affects the quality of life of patients. In this study, we fabricated a niosomal hydrogel containing bromelain to reduce skin collagen and improve skin softness in scleroderma patients. The niosomes were prepared using the thin film hydration method and exhibited a drug loading efficiency of 52.2%. They demonstrated high monodispersity, with mean sizes lower than 200 nm. The results showed a significant reduction in mean dermal thickness from 1195 μm before treatment to 750 μm after the 2-month treatment period. This reduction in dermal thickness and improved skin softness can be attributed to the decomposition of accumulated skin collagen in individuals with scleroderma. Additionally, the treatment was found to be effective in reducing skin collagen levels compared to conventional treatment options that merely impede collagen synthesis. The current study underscores the potential of bromelain niosomal hydrogel as a promising strategy for managing skin fibrosis in scleroderma.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.